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Abstract:  
Drug delivery is the process of transporting a drug to its site of action. It includes controlled 
delivery, where the drug is released at the tissue in a regulated manner. Additionally, it includes 
targeted delivery, where the drug is aimed at a specific tissue or region to avoid unwanted side 
effects (that would occur if the drug were distributed throughout the body). A cellulose acetate 
phthalate coated chitosan bead was developed as a formulation for controlled and targeted 
release of dexamethasone to the ilium and colon. This formulation was determined to be 
effective in delaying dexamethasone release until the formulation had reached conditions that 
simulated the large intestine. Ex vivo characterization using an adapted Franz diffusion cell 
demonstrated that the formulation was able to limit the diffusion of the drug through the 
intestine, which may reduce unwanted side effects as result of the dexamethasone entering the 
systemic circulation.    
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Introduction:  
Patients with Crohn’s Disease present with incurable inflammation of the ileum and colon. This 
results in symptoms such as abdominal pain, chronic diarrhea, weight loss, and rectal bleeding 
[1], which can be treated by anti-inflammatory drugs targeted to the intestines. Several methods 
exist to facilitate this aim: 1) Prodrugs that are inert in the small intestine but are activated by the 
microbiota enzymes; 2) pH sensitive polymers that are used to coat the drug and then degrade at 
a target pH range in the GI tract; and 3) bacterial degradable polymers or matrix/hydrogel 
systems that are broken down by microbiota enzymes to release drug [2]. A bead formulation 
using pH sensitive polymers could, therefore, potentially be a method to deliver an anti-
inflammatory drug and control its release in a temporal and spatial manner. Chitosan is a 
common polymer that has been used previously for colonic drug delivery, due to its selective 
degradation in the colon. Furthermore, chitosan has been shown to be safe for patients with 
Crohn’s disease and does not exacerbate symptoms [3]. An oral formulation would have to 
traverse the GI tract in order to reach the inflamed areas. Gastric juice presents a complication 
for many drugs and delivery methods as the acid tends to dissolve polymers and damage 
molecules. Cellulose acetate phthalate (CAP) is a polymer that is insoluble in the acidic gastric 
environment, making it a good candidate for the enteric coating that will surround the chitosan 
beads. At the intestinal pH of 6.8, the polymer is soluble, allowing dissolution over the course of 
the small intestine [4]. A previous polymer formulation used CAP with a modified chitosan 
(crosslinked with polyethylene glycol) for chemotherapy targeting of the colon [5]. This study 
demonstrates that CAP and chitosan are compatible and may be useful for colon targeting of 
other drugs. Dexamethasone (DEX) is a corticosteroid that acts as an anti-inflammatory agent; 
such drugs are often used as treatments for Crohn's disease [6]. As an immunosuppressant drug, 
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DEX reduces inflammation by inhibiting leukocyte infiltration of the affected area [7]. However, 
IV, IM, or oral corticosteroids can have musculoskeletal side effects such as metabolic bone 
disease, osteoporosis, osteopenia, osteomalacia, and osteonecrosis. Additionally, the risk of 
sepsis can be an issue, since DEX will inhibit immune system function outside the targeted 
region [6]. The CAP coating would allow the beads to safely pass through the stomach and the 
upper intestinal region intact but wear off throughout the rest of the intestines to release DEX 
from the chitosan beads. Accordingly, this would release the drug in the colonic region, provide 
local action at the disease site, and avoid unwanted systemic side effects. Therefore, this CAP 
and chitosan formulation should delay DEX release until the region where the anti-inflammatory 
drug is most needed.   
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Methods:  
Solutions: The 3% (w/v) chitosan solution was prepared by adding 1.2 g of chitosan to 40 ml of 
dH2O and 0.8 ml glacial acetic acid. This solution was stirred for 16 hours at 70°C. The 5% 
(w/v) tripolyphosphate (TPP) solution consisted of 10 g TPP and 200 ml of dH2O, with the pH 
adjusted to 6. The 5% CAP solution was prepared by vortexing 2.5 g of CAP with 47.5 ml of 
acetone and 2.5 ml of a saturated methylene blue solution in acetone. Artificial gastric acid was 
prepared by adding 2.9 ml of 37% HCl to 500 ml of dH2O; the pH was then adjusted to 1.5. 
Artificial intestinal fluid was prepared by adding hydrochloric acid to a pH 7.4 phosphate buffer 
saline (PBS) solution until the pH reached 6.8. The ethanol DEX solution was made by adding 
40 mg of micronized DEX to 2 ml of HPLC grade ethanol. This solution was vortexed for 5 
minutes and sonicated for 15 minutes to form a cloudy saturated solution. The PBS DEX 
solution (for FDC) was made by adding 2.5 mg of micronized DEX to 50 ml of pH 7.4 PBS. 
This was vortexed for 5 minutes and sonicated for 15 minutes until all powder was dissolved. 
The mobile phase for HPLC was 60% Millipore filtered water, 39.5% HPLC grade acetonitrile 
(ACN), and 0.5% of a 10% phosphoric acid solution (v/v). This was mixed and then sonicated 
for 30 minutes to remove dissolved gas.  
Bead preparation: Chitosan beads were formed by dropping 3% (w/v) chitosan at a rate of 0.8 
ml/min into a stirring 5% (w/v) TPP solution. Beads were dropped at a height of 4 cm from the 
surface of the liquid and stirred at 300 rpm. This method, adapted from Shiraishi et al., induced 
crosslinking of the chitosan polymer, and created a porous bead. After 1 hour, the TPP was 
diluted from the stirring solution and the beads were freeze dried for 48 hours at -20°C. The 
dried beads were soaked in a 20 mg/ml DEX solution for 1 hour to allow DEX to penetrate the 
beads. The solvent was evaporated and the beads were washed three times with 100% ethanol. 
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The DEX loaded beads were sprayed in 10 second pulses by ultrasonic atomization of a 5% 
(w/v) CAP solution at 130 KHz, as described by Ganguly et al. This solution also contained 
methylene blue dissolved in acetone, which was used to visualize the CAP layer on the chitosan 
beads. Beads were rotated while the solvent evaporated in a vacuum between pulses to ensure an 
even coating around all sides of the beads. The beads were vacuum dried one final time to 
remove all of the solvent.  
In vitro drug release: In vitro release was tested using an adapted USP-1 method [9].  Equal 
masses of the CAP-coated and noncoated (NC) formulation were placed into seperate USP-1 
baskets. The baskets were submerged in separate 50 ml conical centrifuge tubes that were 
prefilled with 25 ml of artificial gastric acid. 100 μl samples were taken from the sampling port 
in the basket at each time point. The centrifuge tubes were incubated in a 37°C shaking water 
bath at 100 rpm for the duration of the experiment. After 1 hour, the baskets were removed from 
the tubes and dried. The baskets were then submerged in 25 ml of the artificial intestinal fluid 
and returned to the same water bath for the remaining time points. Samples were diluted with the 
mobile phase and filtered with a 22 μm filter prior to High Performance Liquid Chromatography 
(HPLC) analysis.  
Drug loading: A spatula was used to crush and powder each of the formulations. Aliquots of the 
NC and CAP formulation were mixed with 30 ml of 50% methanol and sealed in an Erlenmeyer 
flask. These were sonicated in a water bath for 1.5 hours until the formulation was dissolved. 
The flasks were stirred prior to filtering 1 ml of the solution through a 22 μm filter for HPLC 
analysis.  
HPLC method: Samples were analyzed using an Agilent® Zorbax SB-C18 column (5 μm, 4.6 
mm x 15 cm). Prior to usage, the column was equilibrated with the mobile phase for 1 hour at a 
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flow rate of 1 ml/min. 20 μl of each sample was injected and ran for 6 minutes with detection at 
240 nm. The average retention time for DEX was 4.6 minutes. This peak was integrated and a 
standard curve was used to determine the concentration of DEX in the sample. After all of the 
runs had been completed, the column was washed for 45 minutes with 100% ACN.  
Rat intestine preparation: Rats were fasted for 1 day prior to sacrifice. The large intestine was 
harvested from the cecum to the rectum and suspended in sterile Mammalian Ringer's solution at 
4°C. Intestine segments were flushed with cold pH 7.4 PBS using a blunt end syringe to remove 
any remaining fecal matter. The intestine was incised along the edge of the taeniae coli to 
remove any fat and open the intestine. Each section was cut into squares with a side length of 8 
mm and were kept submerged in cold PBS until the Franz diffusion cells were ready.  
Franz diffusion cell: PermeGear® Franz diffusion cells with a 15 mm orifice diameter were 
fitted with a Teflon washer adaptor to decrease the orifice area. The inner diameter of the adaptor 
was 5 mm and it was 0.5 mm thick. The receptor chamber was filled with 12 ml of pH 7.4 PBS, 
which was stirred at 600 rpm for the duration of the experiment. The cells were allowed to 
equilibrate at 37°C for 1 hour prior addition of the tissue segments. One rat intestine square was 
sandwiched between two adaptors with the lumen facing the donor chamber; this assembly was 
secured with a pinch clamp. 10 mg of the powdered chitosan formulation was added to 10 ml of 
pH 7.4 PBS and stirred at 400 rpm. Immediately, 1 ml of this suspension or 1 ml of the PBS 
DEX solution was added to the donor chamber and the top was sealed. A dispensing needle was 
used to remove a 0.3 mL sample from the sampling port at each time point and sample volume 
was replaced with fresh pH 7.4 PBS. Each sample was run through a 22 μm filter prior to HPLC.  
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Figure 1: Schematic representation of the method of chitosan bead preparation. Chitosan was dropped into 
the stirring TPP solution to create beads, then soaked in a DEX solution. Finally, the DEX loaded beads 
were coated with CAP via pulses of ultrasonic atomization.  
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Results:  
Rounded CAP coated chitosan beads were 
constructed as described in Figure 1. DEX was 
loaded into the beads and the percent of DEX per 
mass of the beads was determined (Table 1). The 
greater drug loading for the noncoated beads can 
be attributed to the additional mass added to the 
formulation during the ultrasonic atomization. 
Since the CAP was stained with methylene blue, 
the CAP coated beads appeared visibly blue, as 
seen in Figure 2.  
The drug release and disintegration of the CAP 
coated and noncoated beads were examined in 
artificial gastric acid for one hour, and then the 
beads were transferred to a pH 6.8 PBS solution 
that simulated the intestinal environment. Within 30 minutes, most of the noncoated beads had 
dissolved into the solution (Figure 3) since chitosan is a hydrophilic polymer that is soluble in 
acid. The CAP coated beads maintained their structural integrity throughout the artificial gastric 
acid condition. CAP is a white polymer, so methylene blue was added to the CAP solution before 
it was sprayed onto the chitosan beads. Consequently, the thickness and coverage of the coating 
could be assessed. The blue CAP coating remained on the beads while in the artificial gastric 
acid, but dissolved in the artificial intestinal fluid (Figure 3). After the CAP coating had worn 
away, the beads began to follow the same disintegration pattern as the noncoated beads in gastric 
  Drug Loading % (w/w) 
CAP 4.545 ± 0.244 
NC 5.298 ± 0.212 
C 
Figure 2: Chitosan beads loaded with DEX, CAP 
coated (A) or noncoated (B). The CAP beads were 
stained with methylene blue. Before coating, the beads 
were crosslinked in a stirring TPP solution (C).   
Table 1: Drug loading percent (w/w) of DEX inside 
the CAP coated beads and noncoated beads. 
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acid, but it was much slower since the pH of the artificial intestinal fluid is closer to neutral. The 
drug release profile was consistent with these observations (Figure 4).  The noncoated beads 
showed an immediate release of DEX, with more than 75% of the total drug released within the 
first half hour in gastric juice. The majority of the drug had already been released before this 
formulation was transferred to the artificial intestinal fluid. The CAP coated beads showed 
limited DEX release in the artificial gastric juice during the first hour of testing. After they were 
transferred to the artificial intestinal fluid, the CAP coated beads quickly released the remaining 
DEX into the neutral pH medium.  
Diffusion of DEX through a section of the large intestine was examined using the Franz 
diffusion cell apparatus, shown in Figure 6. Since the CAP coating would be worn away in the 
small intestine, the powdered noncoated chitosan formulation was compared to the PBS DEX 
solution. The permability data was linearized by plotting the square root of time against the mass 
of DEX that crossed the colon section per area of tissue. In order to compare the formulation to 
the solution, the quantities of DEX measured were scaled to match the difference between the 
drug loading of the formulation and the concentration fo the DEX solution. (Figure 5). The 
diffusion of DEX through the intestine was two-fold greater for the DEX solution than the 
chitosan forulation for the first time point. For the last time point, the diffusion of the DEX 
solution through the intestine was three-fold greater than DEX in the chitosan formulation. Thus 
there was an increasingly greater release over time from the DEX solution. The slope of the least 
squares regression line for the DEX solution was 15.66, whereas the slope of the least-squares 
regression line for the chitosan formlation was 4.873. This indicates that the rate of diffusion of 
DEX was faster for the solution than the formulation.  
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Figure 3: Morphological comparison of 
CAP coated and noncoated (NC) beads. 
The beads were incubated at 37°C at 100 
rpm in artificial gastric acid for one hour 
and then in the artificial intestine fluid for 
the remaining time.  
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Figure 4: Percent of DEX released at each time point for CAP coated beads (blue square) and noncoated beads 
(yellow circle). Beads were in artificial gastric acid (red background) for the first hour and then were switched to 
artificial intestinal fluid (green background) for the remaining time. 
Figure 5: Diffusion of DEX through the large intestine as measured by the Franz diffusion cell. The DEX solution 
showed a faster release (red circles, R² = 0.9964) than the chitosan formulation (blue squares, R² = 0.9775) over four 
hours.  
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Figure 6: Franz diffusion cell adapted to an orifice 
diameter of 5mm. The rat intestine is sandwiched 
between the white Teflon washers. The yellow 
solution in the donor chamber (top) does not leak into 
the receptor chamber (bottom). A water pump was 
used to maintain a temperature of 37°C. 
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Discussion: 
In this study, an enteric coating made of CAP was developed to cover the surface of a chitosan 
bead, which was loaded with DEX (Figure 2). The CAP was stained with methylene blue so that 
the coating thickness could be estimated visually. Furthermore, the status of the coating could be 
observed in the release media by examining the color change over the course of the experiment. 
This CAP coating protected the beads from disintegrating in the artificial gastric juice and the 
CAP coating was subsequently removed in the artificial intestinal fluid. CAP is poorly soluble in 
an acidic environment, so it remained on the beads. However, it is soluble in a pH neutral 
environment, so it dissolves into the artificial intestine fluid.  
Although the chitosan was protected from dissolving in the artificial gastric acid, about 25% of 
the DEX loaded into the beads was still released prior to the pH change. This indicates that the 
CAP coating was either not thick enough or still permeable to DEX. The DEX that was released 
in the stomach would absorb very early in the small intestine. While some forms of Crohn’s 
disease do affect the small intestine, it may be more beneficial to delay the release of the anti-
inflammatory agent even further than the delay achieved with this method. Nonetheless, the CAP 
coated beads released the majority of the DEX in the simulated intestinal environment, so this 
formulation is still superior to the noncoated formulation.  
Figure 4 shows that the noncoated formulation released about 90% of the loaded DEX into the 
artificial gastric acid. This is consistent with the high solubility of chitosan in an acidic 
environment. An acetic acid solution was used to dissolve chitosan to make the beads, which has 
a higher pH than gastric acid. The chitosan dissolved into the artificial gastric acid, resulting in 
the DEX being rapidly released as well. This may also explain why the percent release after the 
basket is switched to the artificial intestine fluid seems to decrease slightly for the noncoated 
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formulation. Since the chitosan was fully dissolved in the acid, it was lost when the basket was 
switched. Consequently, there was no more DEX to be released in those baskets.    
The ex vivo testing of the formulation was performed using a rat intestine as the membrane in a 
Franz diffusion cell. Since the chitosan formulation releases the DEX over the course of several 
hours, the diffusion rate through the intestine squares was lower than a simple DEX solution in 
PBS. Since the beads would be moved down the intestine over the course of several hours, a 
slower diffusion rate may be more advantageous to spread the DEX out over the intestine. The 
DEX solution may be absorbed too quickly in an earlier region of the intestine. Large amounts of 
DEX being absorbed would result in the drug entering the systemic circulation, which would 
increase the potential side effects of this treatment.  
The Franz diffusion cell apparatus can be seen in Figure 6. When the rat intestine is sandwiched 
between the Teflon washers, the tissue tends to sag into the receptor chamber. Intestinal tissue is 
elastic because of the peristaltic movements required to move digested food and fecal matter 
through the GI tract. The area of the tissue exposed to the donor chamber is used to calculate the 
rate that the DEX diffuses through the tissue. This additional curvature would introduce some 
variability into the area, although it would affect all of the tissue samples similarly. Developing a 
way to attach the intestine to the Franz diffusion cell adapter to keep it flat may improve the 
accuracy of the diffusion data. Additionally, DEX may be able to permeate the intestine at 
different rates depending on the segment of the colon, so examining these separately may yield 
important information. 
In conclusion, an enteric coating made of CAP was developed to cover the surface of a chitosan 
bead. These beads were loaded with DEX, a strong anti-inflammatory drug. The CAP coating 
protected the chitosan beads from disintegrating in the artificial gastric juice and the CAP was 
Mendonca 16 
removed in the artificial intestinal fluid. The beads controlled the release of DEX in vitro so that 
the majority of the drug was released in the basic pH of the intestines, rather than the acidic pH 
of the stomach. Using rat intestine segments in a modified Franz diffusion cell, the ex vivo study 
shows that the formulation was able to limit the permeation of DEX through the intestine better 
than the permeation of the PBS DEX solution. These are all characteristics of an ideal Crohn’s 
disease treatment that would help patients manage its unpleasant symptoms.  
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